Skip to main content
. 2017 May 2;23:2096–2103. doi: 10.12659/MSM.901183

Figure 3.

Figure 3

CPS-C enhances oxaliplatin sensitivity in ESCC cell lines TE-1 (A) and TE-2 (B), as determined by MTT assay. Inhibition rates were significantly increased in the CPS-C + oxaliplatin treatment group compared with the oxaliplatin group (P<0.01) at 48 h and were dose dependent.